Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
暂无分享,去创建一个
J. Coyle | D. Goff | D. Manoach | G. Tsai | J T Coyle | D S Manoach | D C Goff | G Tsai | Joseph T. Coyle | Donald C. Goff | Guochan Tsai
[1] T. O'donohue,et al. Glycine modulation of the phencyclidine binding site in mammalian brain , 1988, Brain Research.
[2] J. Fleiss,et al. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. , 1976, Archives of general psychiatry.
[3] D. Javitt,et al. Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.
[4] G. Simpson,et al. A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.
[5] C. Cotman,et al. Excitatory amino acid receptors in schizophrenia. , 1993, Schizophrenia bulletin.
[6] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[7] P. Duffy,et al. Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. , 1989, The Journal of pharmacology and experimental therapeutics.
[8] T. Itil,et al. d-Cycloserine therapy of psychosis by symptom provocation. , 1970, Comprehensive psychiatry.
[9] J. Overall,et al. The Brief Psychiatric Rating Scale , 1962 .
[10] D. Javitt,et al. Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.
[11] P. Francis,et al. d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain , 1991, Brain Research.
[12] Brian A. Lawlor,et al. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? , 1992, Biological Psychiatry.